Research programme: anticancer therapeutics - S*BIO

Drug Profile

Research programme: anticancer therapeutics - S*BIO

Alternative Names: EX2; EX44; EX45; EX58; SB1304; SB1354; SB2312; SB2602

Latest Information Update: 29 Aug 2013

Price : $50

At a glance

  • Originator S*BIO
  • Developer National University of Singapore; S*BIO
  • Class Small molecules
  • Mechanism of Action Cyclin-dependent kinase inhibitors; Enzyme inhibitors; Fms-like tyrosine kinase 3 inhibitors; Histone deacetylase inhibitors; Janus kinase-2 inhibitors; MTOR protein inhibitors; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 29 Aug 2013 This programme is still active
  • 31 Mar 2010 Pacritinib, pracinostat, CT 1578, TG 02 and VS 5584 have been outlicensed prior to March 2010
  • 04 Jan 2008 S*BIO is seeking collaborative and licensing opportunities for compounds arising from this research programme (http://www.sbio.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top